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G

abriel Crane astutely describes the placebo
effect as physiological and psychological
responses that can mitigate signs and
symptoms of several types of disorders, and more
generally, perhaps produce salutory effects (Crane,
2016). Crane rightly notes that placebo effects have
been somewhat enigmatic to both research and medical
practice(s), in part because of inappropriate and/or
insufficient theoretical orientations to the nature of such
responses and effects. In many ways, this reflects the
mechanistic conundrum common to much of Western
science and medicine: we do not accept that something
may or can be effective unless we can demonstrate a
viable mechanism for such effects (Giordano, 2010).
Indubitably, mechanistic understanding is important to
define substrates involved, the potential for these to be
elicited in particular individuals, and if and how such
processes might incur various beneficial/desirable or
deleterious effects.
As Crane has shown, ongoing studies by a
number of groups have been important to elucidating
such mechanisms, and in this way, may have provided
a proverbial “check in the block” toward fortifying
mechanism-to-effect considerations that could
substantiate the viability of use-in-practice (Crane,
2016). Given the substance and findings of this work,
Karen Rommelfanger (2013), like Crane, has queried
whether we are harming patients by withholding placebo
treatment. In attempting to posit an answer I herein
offer that it is – and will be increasingly – important
to contextualize putative mechanisms and empirically
observed effects of placebo to the act of medicine and

clinical encounter. This approach can serve to fortify
a deepened understanding of if, why and how placebo
responses – and the events that evoke them - may be
valid and of value, and how these can and perhaps
should be utilized in clinical practice.
Putative Mechanisms
of Placebo Response(s)
s Crane has reported, several neural loci and
networks are likely engaged in and by placebo
responses. Brainstem systems engage sensory input
from a variety of stimuli from the external and internal
environment to attend to feature orientation and
attendance. Differential activation of reticulo-thalamic
neuraxes involved in attention, emotion and ‘directed’
consciousness (i.e.- ‘consciousness of ’ a circumstance
and the attendant emotional ‘valence’) can create a basal
emotional state that, when taken together with activation
of networks involving the amygdala, insula and regions
of the associative, cingulate, temporal and parietal
cortices, fosters a sense of ‘intentionality’. Concomitant
and/or subsequent engagement of hippocampal, and
parahippocampal cortical neuraxes conjoin working
and declarative memory to frame experience within past
and current circumstance(s). Networks of right and/
or left prefrontal and orbitofrontal cortices participate,
at least to some extent, in higher order expectational
or anticipatory cognitions to afford objectification and
intentionality to situational experience, and relate such
experience to prior, current or potential circumstances.
(Benedetti, Mayberg, Wager, et al, 2005; Kohls, Sauer,
Offenbächer, & Giordano, 2011)
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These mechanisms appear to function in
hierarchical processing. During initial stages of placebo
response, frontal and prefrontal cortices (that contribute
to network processing of expectation), activate the
periaqueductal grey region (PAG) and decrease activity
of the anterior insula, thalamus, and anterior cingulate
gyrus, to evoke direct sensory, rather than perceptual
modulation of physiological input. Late(r) stage placebo
responses involve reduced activity of the anterior and
medial cingulate gyrus and amygdala, and support that
progressive and relatively durable placebo responses
reflect the involvement of other brain loci and networks
(Benedetti, Mayberg, Wager, et al., 2005).

Practical and Ethical Issues:
Toward “Good Use”
t is from this perspective that I concur with Crane
and urge re-examination of the concept – and use - of
placebo. While used in the research literature to refer

to a sham treatment, I offer a more accurate definition
of placebo responses to be those processes that induce
neuropsychological effects that are facilitative to
healing, and which I believe, like Crane, can – and
should - be more validly considered for therapeutic
value in light of current neuroscientific information and
understanding. But any such consideration should not
be cavalier; adherence to clinical equipoise dictates that
like any potential treatment approach, the use of placebo
responses must be weighed against other possible
and viable interventions in light of available evidence,
particulars of the case, and the relative balancing of
benefits, burdens, risks and harms (Giordano, 2008).
Simply put, knowing that a particular treatment can
evoke mechanisms to produce positive outcomes does
not explicitly compel or sustain that it should be used.
Additionally, while placebo responses and
effect(s) may be viewed as valid means to mitigate the
signs and symptoms of certain types of disorders, I
believe, pro philosopher Sisela Bok, that achieving these
means by blatantly lying incurs ethical harms through:
1) intentional deception, 2) undermining the veracity
that establishes and maintains trust within the physicianpatient relationship, 3) denying patients information
necessary for valid informed consent, and 4) impugning
patients’ autonomy, in this sense, the negative right to
refuse particular treatments (Bok, 1974; see also: Gillon,
1985; and Bloche, 2000). This impels consideration of if
and how placebo responses might be ethically achieved
and used in clinical practice.
Disclosing that a certain intervention may
induce placebo responses does not necessarily reduce
the potential for effects, particularly if and when
circumstances in which this information is provided
afford sufficiently positive reinforcement for patients'
expectations of the clinical encounter (Colloca and
Benedetti, 2005; Geers et al. 2005). A physician
could assert that a particular intervention may engage
mechanisms that, in some ways, can reduce feelings
of illness and perhaps evoke physiological recuperative
processes, and that the actual mechanisms of this effect
are not fully known. To be sure, despite myriad advances
in bioscience and technology, in many ways medicine still
remains a relatively uncertain practice. Communicating
this uncertainty to patients with a sense of optimism
allows for veracity and intellectual honesty, while still
fostering trust and hope (Giordano and Boswell, 2005;
Geers et al., 2005; Spiro, 1986).
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Fitting “Treatment” to the “Disorder”:
Research to Indicate “Right Use”
n understanding of these mechanisms is important
when attempting to meet the clinical adage of the
“right treatment for the right diagnosis”. In this light,
ongoing research will be crucial to determining what
works (and what doesn’t), in whom, when, under which
conditions, and what mechanisms are involved. Such
studies can define how psychophysiological variables incur
patient responses and therapeutic outcomes as influential
and applicable, albeit with caveat, to the conduct of the
clinical encounter. Reflecting the Sydenhamian tradition,
the key elements of the clinical encounter are the
determination of 1) what is wrong with the patient, 2) what
can be done (given knowledge of and about the disorder
as expressed in/by the specific patient and the range of
potential interventions that target mechanisms and effects
of the disorder); and from these variables 3) what should
be done. But here it is necessary to recognize the multidimensional nature of “good” relevant to not only what
is biomedically sound, but if and how the application or
engagement of biomedical factors affect an individual
patient’s nature and predicament of illness, circumstances,
values, and choices (Pellegrino and Thomasma, 1993). So,
for those disorders that have been shown to involve neural
substrates that have been demonstrated to be affected in
and by placebo responses, evoking placebo may aptly align
the treatment with the disorder (Giordano 2007).
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Ethico-legal questions also center upon the
cost of interventions that are used to evoke placebo
responses (Bok, 1974). Namely, should these be
billable? One line of rationalization might be that
that if a technique is revealed to produce positive
outcomes (even in the absence of demonstrated specific,
underlying mechanisms for effect), then it is billable
(i.e. - what I call the “valued ends justification”).
Another is that if (even a putative) mechanism is shown
(as is the case, at least in part, for placebo) then this
supports or “confirms” the “reality” of the technique
as scientifically valid, and thus, a billable intervention
(i.e.- the “mechanistic justification”). Lastly, the
mere fact that a clinician must devote x amount of
time to rendering said intervention may be used to
justify incurring costs (i.e., the “professional services”
justification). Each may be sustainable on some level,
and as history has shown, there have been ample
instances of techniques being rendered and patients
billed, without (partial, complete and/or correct)
understanding of underlying mechanism (e.g.- aspirin,
electroshock therapy, lithium, etc.), or even definitive
therapeutic benefit gained. Thus, if it is determined
that placebo may be employed as a (formal) treatment
modality, it will then become necessary to establish
not only particular indications for placebo-inducing
methods, but also billing requirements and treatment
codification for use in practice.
Tools-to-Theory-to-Practice
ncentives of the federal Brain Research through
Advancing Innovative Neurotechnologies (BRAIN)
initiative, to develop and employ new approaches
in neuroimaging, neurogenomics and biomarker
identification and analysis that are specifically oriented
toward and employable in translation of research to
practice will enable more accurate evaluation of if,
how, and in whom certain interventions are effective,
which can fortify a useful corpus of “medicine-based
evidence” (www.whitehouse.gov/BRAIN; Boswell and
Giordano, 2009). Such evidence will be important
to guide both clinical practice and the economics of
patient care, particularly given recent calls for, and
developments in personalized and precision medicine
(see: www.whitehouse.gov/precision-medicine). But
caution is warranted when discerning what types and
levels of evidence have meaning and value, and what
social and economic implications, effects and practices
are derived from these findings (Giordano, 2014; 2010).
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In support of Crane I agree that mechanism and
outcomes’ studies may strengthen consideration of using
placebo as and in clinical practice. As consistent with
Bok (1974), I also claim that using placebo in the clinical
setting may be acceptable if 1) there is an established
clinician-patient relationship; 2) a diagnosis supports
the viability of such intervention and does not mandate
other treatment(s); 3) the patient requires and requests
some form of intervention; 4) it does not interfere with
(other) diagnostic and therapeutic interventions, 5) it
does not incur costs beyond the minimal fees required
for the attendance of the treating clinician, and 6)
other treatments have not been effective. By definition,
placebo responses are those that evoke a positive effect
in the patient. By definition, medicine is a humanistic
endeavor of curing, healing, and caring. In conclusion, I
argue that the former may prove to be important to–and
useful in–the latter. But as with any clinical intervention,
ongoing research, education, ethico-legal insight and
responsibility, and practical wisdom will be essential to
guiding its viability, value, and use in practice.
References

of personality in placebo effects: Dispositional
optimism, situational expectations, and the placebo
response. Journal of Psychosomatic Research 58(2),
121–127. doi:10.1016/j.jpsychores.2004.08.011
Gillon, R. (1985). Telling the truth and medical ethics.
British Medical Journal (Clinical Research and
Education) 291(6508), 1556–1557. doi:10.1136/
bmj.291.6508.1556
Giordano, J. (2014). The human prospect(s) of
neuroscience and neurotechnology: Domains of
influence and the necessity – and questions – of
neuroethics. Human Prospect 4(1), 1-18.
Giordano, J. (2010). The mechanistic paradox: The
relationship of science, technology, ethics and policy.
Synesis: A Journal of Science, Technology, Ethics, and
Policy 1(1), 1-4.
Giordano, J. (2008). Placebo and placebo effects:
Practical considerations, ethical concerns. American
Family Physician 77(9), 1212-1214.
Giordano, J. (2007). Invoking the placebo effect:
Meaning, mechanisms, and morality of the
placebo effect in pain management. Practical Pain
Management 7(4), 73-76.
Giordano, J., Boswell, M. V. (2005). Pain, placebo and
nocebo: Epistemic, ethical, and practical issues. Pain
Physician 8(4), 331–333.
Kohls, N., Sauer, S., Offenbächer, M., & Giordano, J.
(2011). Spirituality - an overlooked predictor of
placebo effects? Philosophical Transactions of the
Royal Society (Biology) 366, 1938-1848. doi:10.1098/
rstb.2010.0389
Pellegrino, E. D., & Thomasma, D. C. (1993). The
virtues in medical practice. New York, NY: Oxford
University Press.
Precision medicine initiative; at: https://www.whitehouse.
gov/precision-medicine; accessed 26. April, 2016.
Rommelfanger, K. S. (2013). Attitudes on mind over
matter: Physician views on the role of placebo in
psychogenic disorders. American Journal of BioethicsNeuroscience 4(3), 9-15.
Spiro, H. M. (1986). Doctors, patients, and placebos. New
Haven, CT: Yale University Press.

Caveats of Placebo Response

International Journal of Transpersonal Studies 151

